Key facts
- Aviceda Therapeutics’s last known valuation is $346.5M (Jan 2025).
- It has raised $276.3M across 3 recorded rounds; the latest was Later Stage VC ($75.0M) in Nov 2024.
- Notable investors include OrbiMed, Catalio Capital Management, Blue Owl Capital, Digitalis Ventures, Logos Capital — 13 tracked in total.
- Aviceda Therapeutics has filed 4 Form Ds with the SEC since 2023, most recently Jan 2025 ($75.0M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Aviceda Therapeutics
Funding rounds
3 roundsAbout Aviceda Therapeutics
Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients. The company combines biology with a cell-based screening platform and proprietary nanoparticle technology to modulate the innate immune response and lead to ophthalmic-optimized nanoparticles, enabling medical researchers to address chronic non-resolving inflammation in patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2018
- Employees
- 33
- Website
- avicedarx.com/
- Ownership
- Privately Held (backing)
Aviceda Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aviceda Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aviceda Therapeutics in its N-PORT filings yet. We sweep new filings monthly.